Accretion Nutraveda IPO GMP, Date, Price Band & Review

Accretion Nutraveda IPO is a book-build issue of ₹24.77 cr, which is entirely a fresh issue of shares. This is a book-building IPO with a price band set at ₹122 to ₹129 per share and the lot size for an application is 1,000. The minimum amount of investment required by an individual investor (retail investor) is ₹2,58,000 (2,000 shares). Accretion IPO will open for subscription on January 28, 2026 and close on January 30, 2026, and it will list on the BSE SME platforms with a tentative listing date fixed as Feb 4, 2026.

Company Background

Accretion Nutraveda Ltd., established in 2021, is a specialized manufacturer of Ayurvedic and Nutraceutical solutions, operating as a robust Contract Development and Manufacturing Organization (CDMO). The company offers a diverse product portfolio across multiple dosage forms, including tablets, oils and powders, targeting critical health areas such as liver care and cognitive support. With a state-of-the-art, WHO-GMP certified facility in Gujarat, it serves prominent markets in the USA and Singapore. Backed by experienced promoters, the firm maintains a strong competitive edge through its dual focus on domestic merchant exports and rapidly growing direct international sales.

Operations and Product Range

Facility and Production

Accretion Nutraveda Ltd. operates a state-of-the-art manufacturing unit in Sanand, Ahmedabad (Gujarat), covering approx 10,763 sq. ft. This facility is highly specialized for Ayurvedic and Nutraceutical production, featuring 13 dedicated air handling units to maintain quality. This company holds prestigious certifications, including WHO-GMP, ISO 9001:2015 and Halal, ensuring global safety standards for various dosage forms.

Brands and Market Presence

Accretion Nutraveda has established a significant footprint in over 20 countries, including the USA, Singapore and Sri Lanka. As a key CDMO player, it supports both large corporate clients and specialty brands. Its market presence is anchored by a portfolio of over 400 formulations addressing therapeutic areas like liver care, respiratory wellness and women’s health.

Revenue Channels

• • Domestic sales and Merchant exports that contribute 96.62% of the total revenue.
• • Direct exports in various markets, like Sri Lanka, Singapore, the USA and more.

Management and Shareholding

Promoters and Shareholding

Accretion Nutraveda IPO is led by promoters Mayur Popatlal Sojitra, Ankurkumar Shantilal Patel and Paraskumar Vinubhai Parmar, who held 100% of the equity pre-issue. Post-IPO, their stake is expected to adjust to approx 73.48%. This percent indicates a significant commitment from the founding team while allowing for public participation to fund automation and expansion goals.

Board Members

The board members of this company is led by Managing Director Mayur Sojitra, an MBA from London with a decade of pharma experience. Accretion Ltd. get supported by Whole-time Director Ankurkumar Patel, an expert in Ayurvedic science and CFO Paraskumar Parmar. The board also includes Independent Directors like Arun Dash and Shruti Gupta, who ensure strong corporate governance and regulatory compliance.